About Contact Us Careers

Neuromuscular Blocking Drugs Market Size

Request Free Sample Copy

Report ID: 2564
Published Date: Oct 15, 2024
Report Format: PDF, PPT

Buy Now

Neuromuscular Blocking Drugs Market Size

Neuromuscular Blocking Drugs Market size was valued at USD 5.34 billion in 2023 and is set to exceed USD 9.35 billion by 2036, registering over 4.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of neuromuscular blocking drugs is evaluated at USD 5.53 billion.

Rising number of people across the world are opting for surgical treatments on account of increasing disposable incomes and proven accuracy of surgeries. Moreover, the usage of neuromuscular blocking drugs in surgeries is increasing. Owing to these factors,

Neuromuscular Blocking Drugs Market Graph

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Neuromuscular Blocking Drugs Market Size & Share, Growth Report 2036

Author Credits: Radhika Pawar

Report ID: 2564
Published Date: Oct 15, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of neuromuscular blocking drugs is evaluated at USD 5.53 billion.

Neuromuscular Blocking Drugs Market size was valued at USD 5.34 billion in 2023 and is set to exceed USD 9.35 billion by 2036, registering over 4.4% CAGR during the forecast period i.e., between 2024-2036.

North America industry is likely to account for largest revenue share by 2036, backed by high geriatric population, increasing research and development initiatives by the government, increasing safety and efficacy of the drug and more number of people opting for surgical treatments.

The major players in the market are Hikma Pharmaceuticals PLC, Merck & Co. Inc., Novartis AG, Bayer AG, Roche Inc., Zydus Cadila, Pfizer, AbbVie Inc., Abbott Healthcare, GlaxoSmithKline PLC, Neurana Pharmaceuticals, Teva Pharmaceuticals, and others.

Inquiry Before Buying Request Free Sample